Prediabetes Market Size, Share & Trends Analysis Report By Drug Class (Diguanide, Thiazolidinediones), By Age Group (Children, Adult), By Region, And Segment Forecasts, 2024 - 2030

Prediabetes Market Size & Trends

The global prediabetes market size was estimated at USD 201.62 million in 2023 and is projected to grow at a CAGR of 7.21% from 2024 to 2030. The increasing incidence of conditions leading to insulin resistance and impaired glucose metabolism, stemming from mutations in specific genes, serves as the primary driver of the prediabetes market. Prediabetes is a condition characterized by elevated blood sugar levels that are not high enough to be classified as Type 2 diabetes. The normal blood glucose level ranges from 70 to 99 milligrams per deciliter (mg/dL).

In individuals with prediabetes, blood glucose levels are typically between 100 to 125 mg/dL According to an article published in the BMC Public Health journal in May 2023, the global prevalence of prediabetes was estimated to be 319 million in 2021 and projected to increase to 441 by 2045. Additionally, the rising prevalence of various associated risk factors, such as sedentary lifestyles, obesity, and unhealthy dietary patterns, contributes significantly to market expansion.

Prediabetes refers to an intermediate stage of glucose dysregulation situated between standard glucose tolerance and diagnosed diabetes. People with prediabetes exhibit elevated blood glucose levels exceeding the normal range but haven't met the criteria for a diabetes diagnosis. Terms such as impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are utilized to characterize this prediabetic condition. According to the National Center for Biotechnology Information (NCBI), in 2021, an estimated 464 million adults aged 20 to 79 years were projected to have IGT, while 298 million were estimated to have IFG. These numbers are anticipated to rise to 638 million for IGT and 414 million for IFG cases by 2045.

The growing use of anti-diabetic medications like Metformin, aimed at reducing sugar production and absorption in the body to prevent disease progression, positively impacts market growth. Metformin, an antidiabetic medication, gained approval from the U.S. Food and Drug Administration (FDA) in 1994 as a treatment for type 2 diabetes. Available in immediate and extended-release forms, it is frequently combined with other antidiabetic drugs.

Moreover, the rising adoption of continuous glucose monitoring (CGM) devices, which provide real-time feedback on glucose levels and facilitate management actions, further strengthens market growth. These gadgets prove beneficial in overseeing diabetes among groups like toddlers, pregnant individuals, the elderly, and those with concurrent health conditions. Furthermore, individuals with prediabetes find value in utilizing CGM technology. For instance, according to the National Center for Biotechnology Information (NCBI), in March 2023, individuals with prediabetes experienced heightened postprandial glucose levels, and the utilization of CGM could trigger behavioral modifications, potentially postponing the onset of diabetes. The increasing adoption of technology for diagnosing prediabetes in turn boosts the demand for its treatment.

Market Concentration & Characteristics

Innovations in the prediabetes market are driving significant progress, with advanced diagnostic tools enabling early detection. Personalized treatment approaches and emerging therapeutics aim to cease disease progression. Digital health solutions enhance patient monitoring and engagement. These innovations are reshaping prediabetes management, improving outcomes, and reducing the risk of type 2 diabetes.

Several market players such as Novo Nordisk, Caelus Health and Boston Therapeutics, are involved in merger and acquisition activities. These M&A endeavors aim to capitalize on emerging opportunities and drive innovation in prediabetes management solutions.

Regulations in the market have a significant impact, driving industry players to invest in advanced technologies and quality assurance measures. Compliance with regulatory frameworks ensures patient safety, fosters innovation, and establishes trust among customers.

In the prediabetes market, alternative products or substitutes may include lifestyle interventions such as diet and exercise programs and over-the-counter supplements and herbal remedies. These substitutes offer non-pharmacological approaches to managing prediabetes and may be favored by individuals seeking natural or holistic solutions.

Expansion of the prediabetes market into new regions involves entering untapped geographical areas to reach a wider population. This expansion strategy aims to increase market penetration, capture new customers, and capitalize on emerging opportunities. It involves adapting to regional preferences, regulatory requirements, and healthcare infrastructure to address local needs effectively.

Age Group Insights

Based on age group, the adults (18-49) segment held the market with the largest revenue share of 48.8% in 2023. The adult age group consists of individuals from age 18-49. This age group has reported the highest prevalence of prediabetes. For instance, according to CDC, about 38% of all U.S. adults had prediabetes as per 2021 estimates. The high prevalence of prediabetes in this age group coupled with the increased adoption of unhealthy lifestyles are driving the growth of this age group segment.

The elderly segment is expected to grow at a lucrative CAGR during the forecast period. The adult age group consists of individuals above the age of 50. The elderly population is highly prone to developing prediabetes due to metabolic deteriorations that occur during the process of aging. According to CDC, in the U.S. about 27.2 million people aged 65 years and above have prediabetes as per 2021 estimates. The increasing geriatric population globally along with increasing medication options available for the treatment of prediabetes are expected to drive the growth of this segment.

Drug Class Insights

Based on drug class, the diguanides segment led the market with the largest revenue share of 83.8% in 2023. Biguanides is a class of drugs that includes metformin. They are widely used in the treatment of prediabetes and type 2 diabetes. Currently, metformin is the most commonly prescribed biguanide for the treatment of prediabetes. For instance, according to the National Center for Biotechnology Information (NCBI) in August 2023, Metformin stands as the sole American Diabetes Association (ADA)-recommended medication for managing prediabetes in both adult and pediatric patients 10 or older. According to Standards of Medical Care in Diabetes 2022, identifying individuals with prediabetes may involve considering a glycated hemoglobin A1C test range of 5.7-6.4% (39-47 mmol/mol) as reasonable.

The SGLT2 inhibitors segment is expected to grow at a lucrative CAGR during the forecast period. SGLT2 inhibitors are increasingly being used for the treatment of prediabetes in recent times. This class of drugs acts by inhibiting the reabsorption of sugar from the urine. This leads to loss of glucose through urine and decreases the blood sugar level. Some of the drugs in this class include dapagliflozin, sotagliflozin, canagliflozin, empagliflozin, and ertugliflozin. The comparatively low side effects, and high efficacy of these drugs are some of the factors leading to market growth.

Regional Insights

North America region dominated the market with the revenue share of 41.5% in 2023. Increasing awareness about the importance of early detection and intervention for prediabetes, coupled with rising prevalence rates, is fueling market expansion. For instance, according to American Diabetes Association (ADA) in 2021, prediabetes was observed in 97.6 million adults aged 18 and above in the U.S. In addition, advancements in diagnostic technologies and therapeutic options are enhancing the effectiveness of prediabetes management strategies. Moreover, supportive healthcare policies and initiatives aimed at addressing prediabetes risk factors contribute to market growth.

U.S. Prediabetes Market Trends

The prediabetes market in the U.S. held the largest share in 2023, owing to key factors such as increasing geriatric population, which drives demand for screening, diagnostic, and management solutions. Secondly, technological advancements, such as wearable devices and digital health platforms, are revolutionizing prediabetes management by enabling continuous monitoring and personalized interventions. In addition, there is a shift towards holistic approaches to prediabetes management, including lifestyle modifications and nutritional interventions.

Europe Prediabetes Market Trends

The Europe region is expected to grow at a significant CAGR over the forecast period, due to high prevalence of prediabetes, increased adoption of disease causing lifestyles, well developed healthcare infrastructure, and emphasis on early disease detection.

The prediabetes market in UK is projected to expand in the future, driven by factors like heightened awareness, advancements in diagnostic technology, and a focus on early diagnosis. These factors are forecasted to boost the demand for prediabetes therapeutics. According to Diabetes.co.uk, in September 2022, approximately 7 million individuals in the UK are estimated to have prediabetes, placing them at a heightened risk for type 2 diabetes.

The Germany prediabetes market is expected to grow at the fastest CAGR over the forecast period. This growth is fueled by factors like increased physical inactivity and adoption of unhealthy dietary habits, which lead to the development of prediabetes.

In France, factors influencing the prediabetes market include increased awareness and advancements in diagnostic technologies such as CGM. Collaborative efforts among healthcare stakeholders are also pivotal in enhancing preventive measures and improving outcomes in prediabetes management. For instance, in November 2023, Valbiotis in France recently announced the successful results of the TOTUM•63 clinical study targeting prediabetes and early stages of type 2 diabetes.

Asia Pacific Prediabetes Market Trends

The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, firstly due to rising urbanization and adoption of sedentary lifestyles contributing to the increasing prevalence of prediabetes. Secondly, genetic predisposition and dietary habits, including high consumption of sugary and processed foods, play a role in predisposing individuals to prediabetes. In addition, aging populations and changing demographics contribute to the growing burden of prediabetes in the region.

Various factors impact the prediabetes market in China. Cultural perspectives and attitudes towards health and well-being affect healthcare-seeking behaviors and approaches to managing prediabetes. Moreover, the aging population and increasing obesity rates worsen the situation. According to Science Direct, in March 2023, approximately one-third of China's population has prediabetes.

The prediabetes market in Japan is expected to grow at the fastest CAGR over the forecast period. According to the National Center for Biotechnology Information (NCBI), in February 2023, In Japanese adolescents, particularly those who are overweight, skipping breakfast was linked to prediabetes. Encouraging the avoidance of skipping breakfast could aid in preventing prediabetes. In addition, heightened awareness of the link between skipping breakfast and prediabetes could lead to increased demand for diagnostic tests and screening services among healthcare providers, further driving market growth.

Key Prediabetes Company Insights

Some of the key players operating in the market include Novo Nordisk, Valbiotis, and RESVERLOGIX. The company's primary strategies involve a comprehensive understanding of the strengths and weaknesses of major market participants, anticipation of future market trends, identification of opportunities and challenges, and proactive decision-making based on insights into emerging technologies and evolving consumer preferences.

Caelus Health, and SciMar. are some of the emerging market players in the global market. These market players are continuously focused on niche segments, leveraging specialized technologies to differentiate themselves.

Recent Developments

• In September 2023, Valbiotis and Nestlé Health Science intend to introduce a dietary supplement in 2024 tailored for individuals with prediabetes and type-2 diabetes, following promising outcomes from a recent study demonstrating the product's effectiveness in improving critical indicators of glucose metabolism

• In November 2023, VALBIOTIS SA announced the success of its product TOTUM•63 in the mode of action clinical study for the treatment of prediabetes

• In April 2023, Aphaia Pharma announced initiation of its Phase 2 Trial for its drug candidate APH-012 for the treatment of prediabetes

• In January 2024, Novo Nordisk announced the launch of its Wegovy, a GLP-1 analogue in the U.K. This drug can be prescribed to people with prediabetes and for weight loss purposes

Prediabetes Market Report Scope

Global Prediabetes Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global prediabetes market report based on drug class, age group, and region:

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Diguanide

  • Thiazolidinediones

  • Glucagon-like Peptide-1 Agonists (GLP-1)

  • SGLT2 Inhibitors

  • DPP-4 Inhibitors

  • Others

• Age group Outlook (Revenue, USD Million, 2018 - 2030)

  • Children (12-18 years)

  • Adults (18-49)

  • Elderly (50+)

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait